FDA Approves Merck RSV Shot for Infants — Despite High Rates of Serious Reactions
The U.S. Food and Drug Administration has recently approved clesrovimab, Merck’s new shot touted to “protect” infants against respiratory syncytial virus (RSV).1 This approval comes despite…






